Kyntra Bio, Inc.
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and… Read more
Kyntra Bio, Inc. - Asset Resilience Ratio
Kyntra Bio, Inc. (KYNB) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2024)
This chart shows how Kyntra Bio, Inc.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Kyntra Bio, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Kyntra Bio, Inc. maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Kyntra Bio, Inc. Industry Peers by Asset Resilience Ratio
Compare Kyntra Bio, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Kyntra Bio, Inc. (2012–2024)
The table below shows the annual Asset Resilience Ratio data for Kyntra Bio, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | $0.00 | $214.53 Million | -- |
| 2023-12-31 | 28.78% | $121.90 Million | $423.53 Million | -14.87pp |
| 2022-12-31 | 43.65% | $266.31 Million | $610.09 Million | +13.42pp |
| 2021-12-31 | 30.24% | $233.97 Million | $773.82 Million | +29.25pp |
| 2020-12-31 | 0.98% | $8.14 Million | $826.84 Million | -46.54pp |
| 2019-12-31 | 47.53% | $407.49 Million | $857.40 Million | -12.90pp |
| 2018-12-31 | 60.43% | $532.14 Million | $880.60 Million | +53.52pp |
| 2017-12-31 | 6.91% | $62.06 Million | $898.65 Million | -10.00pp |
| 2016-12-31 | 16.91% | $79.40 Million | $469.55 Million | +10.99pp |
| 2015-12-31 | 5.92% | $27.85 Million | $470.57 Million | +2.95pp |
| 2014-12-31 | 2.97% | $14.36 Million | $483.53 Million | -12.68pp |
| 2013-12-31 | 15.65% | $46.48 Million | $296.95 Million | +15.27pp |
| 2012-12-31 | 0.38% | $1.02 Million | $265.59 Million | -- |